|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
UNDER CONSTRUCTION | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Wednesday, November 08, 2006MBP8298: New Drug in the Pipeline...Ryan Giese gave me this message for you:Click Here to go to Bioms Medical's Home Page "Hi Stan, It was nice talking to you again! BioMS has one mission: to deliver a safe and effective treatment for MS patients and we are well on our way. MBP8298 is based on ground-breaking research and has successfully completed phase I and II clinical trials. Currently we are in an international phase III trial for secondary progressive MS in Canada and Europe. BioMS expects to commence a similar phase III trial in the US in the first half of 2007. Recently the European Journal of Neurology published data that showed MBP8298 safely delayed disease progression in an HLA-defined subgroup of MS patients for an unprecedented 5 years. It is my hope that all MS patients can potentially benefit from this exciting research. Please feel free to call me if you need any more information on MBP8298. I will give you any information that we are able to release to the public...immediately...so you can give it to your MS patients and their families" Ryan Giese Vice President Corporate Communications BioMS Medical Corp |